An electrolyte including an additive of compound of formula I,

##STR00001## wherein n is an integer ranging from 0 to 10; R.sub.1 and R.sub.2 are each independently selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, or a substituted or unsubstituted C.sub.1-C.sub.10 alkyleneoxy group; Ai selected from CH, C, N, S, O, B or Si; A.sub.2 is selected from CH—R.sub.3, N—R.sub.3, S, O, B—R.sub.3 or SiH—R.sub.3; A.sub.3 selected from CH.sub.2, CH, C, N, S, O, B or Si; R.sub.3 is selected from hydrogen, halogen, a substituted or unsubstituted C.sub.1-C.sub.10 alkyl group, or a substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl group; Xi is selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, ═R.sup.c═, or ═R.sup.c—, wherein R.sup.c is selected from a substituted or unsubstituted C.sub.2-C.sub.6 alkylidene group.

An electrolyte including an additive of compound of formula I,

##STR00001## wherein n is an integer ranging from 0 to 10; R.sub.1 and R.sub.2 are each independently selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, or a substituted or unsubstituted C.sub.1-C.sub.10 alkyleneoxy group; Ai selected from CH, C, N, S, O, B or Si; A.sub.2 is selected from CH—R.sub.3, N—R.sub.3, S, O, B—R.sub.3 or SiH—R.sub.3; A.sub.3 selected from CH.sub.2, CH, C, N, S, O, B or Si; R.sub.3 is selected from hydrogen, halogen, a substituted or unsubstituted C.sub.1-C.sub.10 alkyl group, or a substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl group; Xi is selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, ═R.sup.c═, or ═R.sup.c—, wherein R.sup.c is selected from a substituted or unsubstituted C.sub.2-C.sub.6 alkylidene group.

The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.

The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11a, R.sup.11b, R.sup.11c, R.sup.11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11a, R.sup.11b, R.sup.11c, R.sup.11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Localized high-salt-concentration electrolytes each containing a salt, a glyme as a solvent, and a fluorinated diluent. In some embodiments, the glyme has a chemical formula R.sub.1—(O—CH.sub.2—CH.sub.2).sub.n—O—R.sub.2, wherein n=1 to 4 and at least one of R.sub.1 and R.sub.2 is a hydrocarbon sidechain having at least 2 carbon atoms and wherein the salt is soluble in the glyme. In some embodiments, the fluorinated diluent is selected from the group consisting of a fluorinated glyme and a fluorinated ether. In some embodiments, the salt includes an alkali-metal salt. In some embodiments, the salt includes an alkali-earth-metal salt. The salt may include a perfluorinated sulfonimide salt. Electrochemical devices that include localized high-salt-concentration electrolytes of the present disclosure are also disclosed.

Localized high-salt-concentration electrolytes each containing a salt, a glyme as a solvent, and a fluorinated diluent. In some embodiments, the glyme has a chemical formula R.sub.1—(O—CH.sub.2—CH.sub.2).sub.n—O—R.sub.2, wherein n=1 to 4 and at least one of R.sub.1 and R.sub.2 is a hydrocarbon sidechain having at least 2 carbon atoms and wherein the salt is soluble in the glyme. In some embodiments, the fluorinated diluent is selected from the group consisting of a fluorinated glyme and a fluorinated ether. In some embodiments, the salt includes an alkali-metal salt. In some embodiments, the salt includes an alkali-earth-metal salt. The salt may include a perfluorinated sulfonimide salt. Electrochemical devices that include localized high-salt-concentration electrolytes of the present disclosure are also disclosed.

The present application provides malonamide compounds, and derivatives thereof (e.g., N-aryl malonamides (NAM), acetamides, oxalamides, and the like), that are useful, for example, for the treatment of acute, chronic/persistent, and/or relapsing infections. Pharmaceutical compositions, methods of treating diseases (e.g., bacterial infections), and methods of reducing bacterial virulence are also provided.

Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.